Potential prognostic value of C-erbB-2 expression in medulloblastomas in very young children

Journal of Pediatric Hematology/Oncology

Volumn 19, Issue 6, 1997, Pages 510-515

  Herms, Jochen W ^a   Behnke, Julianne ^b   Bergmann, Markus ^b   Christen, Hans Jürgen ^b   Kolb, Reinhard ^b   Wilkening, Martin ^b   Markakis, Evangelos ^b   Hanefeld, Folker ^b   Kretzschmar, Hans A ^b  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b NONE

Author keywords

C erbB 2; Childhood; Medulloblastoma; Prognosis; Survival

Indexed keywords

GENE PRODUCT; GLIAL FIBRILLARY ACIDIC PROTEIN; MONOCLONAL ANTIBODY; SYNAPTOPHYSIN;

ADOLESCENT; ARTICLE; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM TUMOR; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; HUMAN; HUMAN TISSUE; INFANT; MEDULLOBLASTOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTO ONCOGENE;

ADOLESCENT; ANTIBODIES, MONOCLONAL; CEREBELLAR NEOPLASMS; CHILD; CHILD, PRESCHOOL; FEMALE; GENE EXPRESSION; GENES, ERBB-2; HUMANS; INFANT; MALE; MEDULLOBLASTOMA; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTOR, ERBB-2;

EID: 0031425176     PISSN: 10774114     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-199711000-00004     Document Type: Article

References (27)

1. Biegel JA, Burk CD, Barr FG, et al. Evidence for a 17p tumor related locus distinct from p53 in pediatric primitive neuroectodermal tumors. Cancer Res 1992;52:3391-5.
2. Biegel JA, Roke LB, Janss AJ, et al. Isochromosome 17q demonstrated by interphase fluorescence in situ hybridization in primitive neuroectodermal tumors of the central nervous system. Genes Chromosomes Cancer 1995;14:85-96.
3. Albrecht S, von Deimling A, Pietsch T, et al. Microsatellite analysis of loss of heterozygosity on chromosomes 9q, 11p and 17p in medulloblastomas. Neuropathol Appl Neurobiol 1994;20:74-81.
4. Cogen PH, Daneshvar L, Metzger AK, et al. Involvement of multiple chromosome 17p loci in medulloblastoma tumorgenesis. Am J Hum Genet 1992;50:584-9.
5. Batra SK, McLendon RE, Koo JS, et al. Prognostic implications of chromosome 17p deletions in human medulloblastomas. J Neurooncol 1995;24:39-45.
6. Emadian SM, McDonald JD, Gerken SC, et al. Correlation of chromosome 17p loss with clinical outcome in medulloblastoma. Clin Cancer Res 1996;2:1559-64.
7. Wasson JC, Saylors RL, Zeltzer P, et al. Oncogene amplification in pediatric brain tumors. Cancer Res 1990;50:2987-90.
8. Allen JC. Medulloblastoma and other primary malignant neuroectodermal tumors of the CNS. The effect of patient age and extent of disease on prognosis. J Neurosurg 1982;57:446-51.
9. Caputy AJ, McCullough DC, Manz HJ, et al. A review of the factors influencing the prognosis of medulloblastoma. The importance of cell differentiation. J Neurosurg 1987;66:80-7.
10. Jenkin D, Goddard K, Armstrong D, et al. Posteria fossa medulloblastoma in childhood. Treatment results an a proposal of a new staging system. Int J Radiat Oncol Biol Phys 1990;19:265-74.
11. Zerbini C, Gelber RD, Weinberg D, et al. Prognostic factors in medulloblastoma, including DNA ploidy. J Clin Oncol 1993;11:616-22.
12. Packer RJ, Sutton LN, Rorke LB, et al. Prognostic importance of cellular differentiation in medulloblastoma of childhood. J Neurosurg 1984;61:296-301.
13. Gilbertson RJ, Jaros EB, Perry RH, et al. Prognostic factors in medulloblastoma. Lancet 1992;340:8817.
14. Gilbertson RJ, Pearson AD, Perry RH, et al. Prognostic significance of the c-erbB-2 oncogene product in childhood medulloblastoma. Br J Cancer 1995;71:473-7.
15. Gullick WJ, Love SB, Wright C, et al. C-erb B2 overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br J Cancer 1991;63:434-8.
16. Scheeler A, Stern D, Vaidyanathan L, et al. The neu-oncogene; an erb B-related gene encoding a 185,000 MR tumour antigen. Nature 1984;312:513-6.
17. Lovekin C, Ellis IO, Locker O, et al. C-erbB-2 oncoprotein expression in primary and advanced breast cancer. Br J Cancer 1991;63:439-43.
18. Wright C, Angus B, Nicholson S, et al. Expression of c-erbB-2 Oncoprotein: A prognostic indicator in human breast cancer. Cancer Res 1989;49:2087-90.
19. Van De Vijver MJ, Peterse JL, Mooi WJ, et al. Neu-protein overexpression in breast cancer: association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med 1988;319:1239-45.
20. Corbett IP, Henry JA, Angus B, et al. NCL-CB11, a new monoclonal antibody recognizing the internal domain of the c-erbB-2 oncogene protein effective for use on formalin-fixed, paraffin-embedded tissue. J Pathol 1990;161:15-25.
21. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
22. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. Br J Cancer 1977;35:1-39.
23. Marchionni MA, Goodearl ADJ, Chen MS, et al. Glial growth factors are alternatively spliced erbB2 ligands expressed in the nervous system. Nature 1993;362:312-8.
24. Lee K-F, Simon H, Chen H, et al. Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature 1995;378:394-8.
25. Gutman M, Ravia Y, Assaf D, et al. Amplification of c-myc and c-erbB-2 proto-oncogene in human solid tumors: Frequency and clinical significance. Int J Cancer 1989;44:802-5.
26. Fukushige SI, Matsubara KI, Yoshida M, et al. Location of a novel v-erb B related gene c-erb B2 on human chromosome 17 and its amplification in a gastric cancer cell line. Mol Cell Biol 1986;6:955-8.
27. Bigner SH, Mark J, Friedman HS, et al. Strctural chromosomal abnormalities in human medulloblastomas. Cancer Genet Cytogenet 1988;30:91-101.